In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Senate budget

This article was originally published in The Gray Sheet

Executive Summary

Appropriations Committee approves $1.1 bil. increase to NIH budget at Sept. 15 mark-up, bringing agency to $28.91 bil. for FY 2005. The Senate version represents an increase over a Sept. 9 House budget earmarking $28.51 bil. for NIH. The Senate bill echoes House recommendations that CMS develop a wheelchair coverage policy "firmly based on a functional standard" of what it means for a patient to be "non-ambulatory," including "beneficiaries who cannot perform their basic acts of daily living, toileting, food preparation and emergency egress." The Senate and House both note the cost-effectiveness of avoiding institutional care or hospitalization. At a Sept. 1 town meeting, CMS had proposed new payment codes to help combat power wheelchair fraud (1"The Gray Sheet" Sept. 6, 2004, p. 15)...

You may also be interested in...



Medicare Revisits Power-Wheelchair Codes; ECRI Wants More iBOT Studies

ECRI recommends larger, longer-term studies of Johnson & Johnson/Independence Technology's iBOT 3000 stair-climbing power wheelchair to better determine the device's cost-to-benefit ratio

FDA Slacking In NDI Notification Enforcement; COVID-19 'Is Not An Excuse’ – NPA

In a statement submitted to the Senate Finance Committee, Natural Products Association CEO Dan Fabricant suggests two ways of improving compliance with new dietary ingredient notification requirements at negligible expense to the US FDA.

Finance Watch: Four IPOs In One Week, And Legend Is Year’s Largest So Far

Public Company Edition: Legend Biotech raised $424m in its US public market debut. Also, Pfizer commits up to $500m for equity investments and Allogene capitalizes on ASCO with a $550m offering.

UsernamePublicRestriction

Register

PL000723

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel